Although the majority of patients with lung adenocarcinoma harboring sensitizing EGFR mutations respond to EGFR-TKIs including osimertinib, efficacy is limited by the universal development of acquired resistance. The gene discussed is EGFR; the disease is lung adenocarcinoma.